http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7887818-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cea139ad438b9ce7d33159d45b154c6b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate | 2008-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_326d84f4b2f47cd59cc67c92fc9ce587 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d84ed2b57c219813a904a09e1d86ca0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_883b11cef0aa347a5f1ab4ea36021d42 |
| publicationDate | 2011-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7887818-B2 |
| titleOfInvention | Neospora caninum vaccine |
| abstract | Neospora caninum is the causal agent of bovine neosporosis which results in high levels of abortion. The protective efficacy of two Neospora antigens: Neospora cyclophilin (NcCyP) and NcSRS2 was evaluated. Mice vaccinated with recombinant (r) NcCyP, rNcSRS2, and the combination rNcCyP plus rNcSRS2, formulated with adjuvant ImmuMax-SR® and CpG were challenge-infected 3 weeks following the booster immunization and necropsied 3 weeks after the challenge infection. Mice vaccinated with rNcCyP, rNcSRS2, or the combination of rNcCyP and rNcSRS2 responded with high levels of NcCyP- or NcSRS2- specific antibodies. Mice which received vaccines formulated with either rNcCyP or the combination rNcCyP and rNcSRS2 had a higher (p<0.01) percent protection when compared to the mock- or non-vaccinated mice. Groups immunized with rNcSRS2 alone exhibited slightly lower levels of protection. Results indicate that NcCyP is a highly efficacious vaccine candidate useful in protection against Neospora infection. |
| priorityDate | 2008-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 106.